Stacy S. Shord
- Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism 15
- Oncology top 2%
- Cancer Treatment and Pharmacology 13
- Colorectal Cancer Treatments and Studies 6
- Hematology top 5%
- Erythropoietin and Anemia Treatment 4
- Infectious Diseases top 5%
- Genetics top 10%
-
- Statistical Methods in Clinical Trials 7
-
- Lung Cancer Treatments and Mutations 6
-
- Acute Lymphoblastic Leukemia research 6
-
- Pharmaceutical studies and practices 4
- Co-authors
- Richard PazdurAnn T. FarrellCeleste LindleyDonna PrzepiorkaLei NieWeishi YuanEdward L. LeCluyseRobert Q. Le
- Cited by
- PharmacologyOncologyHematology
- Journals
- Journal of Clinical Oncology (6 papers)Cancer Research (1 paper)Clinical Cancer Research (9 papers)
- Partner nations
- United StatesBelgiumItaly
In The Last Decade
Stacy S. Shord
66 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Pharmacology 458
- Oncology 1.0k
- Hematology 274
- Infectious Diseases 272
- Genetics 153
Countries citing papers authored by Stacy S. Shord
This map shows the geographic impact of Stacy S. Shord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacy S. Shord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacy S. Shord more than expected).
Fields of papers citing papers by Stacy S. Shord
This network shows the impact of papers produced by Stacy S. Shord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacy S. Shord. The network helps show where Stacy S. Shord may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Stacy S. Shord, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 6 | |
| 6 | 2020 | 8 | |
| 7 | FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemiabreakdown → | 2018 | 252 |
| 8 | FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndromebreakdown → | 2018 | 610 |
| 9 | 2018 | 53 | |
| 10 | 2013 | 9 | |
| 11 | 2013 | 25 | |
| 12 | 2010 | 28 | |
| 13 | 2010 | 3 | |
| 14 | 2009 | 6 | |
| 15 | 2009 | 21 | |
| 16 | Gene expression ratio of deoxycytidine kinase (dCK) to cytidine deaminase (CDA) corresponds with cytotoxicity in solid tumors in vitro | 2008 | 2 |
| 17 | 2008 | 13 | |
| 18 | 2007 | 3 | |
| 19 | 2006 | 20 | |
| 20 | 2003 | 28 |
About Stacy S. Shord
Stacy S. Shord is a scholar working on Pharmacology, Hematology and Oncology, having authored 69 papers that have together received 2.7k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (15 papers), Cancer Treatment and Pharmacology (13 papers), Statistical Methods in Clinical Trials (7 papers), Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Acute Lymphoblastic Leukemia research (6 papers), Erythropoietin and Anemia Treatment (4 papers) and Pharmaceutical studies and practices (4 papers). The work is most often cited by research in Pharmacology (458 citations), Oncology (1.0k citations) and Hematology (274 citations). Stacy S. Shord has collaborated with scholars based in United States, Belgium and Italy. Frequent co-authors include Richard Pazdur, Ann T. Farrell, Celeste Lindley, Donna Przepiorka, Lei Nie, Weishi Yuan, Edward L. LeCluyse, Robert Q. Le, Liang Li and Bahru Habtemariam. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.